#FULC

Fulcrum Therapeutics (Nasdaq: FULC) starts proposed $150.0M raise, plus $22.5M option Fulcrum Therapeutics begins a proposed $150.0M common stock offering with a $22.5M underwriter option, aiming to fund R&D, trials, and broader corporate needs.

3 months ago

#FULC Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock

www.stocktitan.net/news/FULC/fulcrum-therap...

0 0 0 0

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025 Fulcrum Therapeutics (NASDAQ: FULC) reported Q3 2025 results and clinical updates on Oct 29, 2025. Key clinical news: encouraging Phase 1b PIONEER 12 mg cohort results showing dose-dependent fetal hemoglobin (HbF) increases, hemolysis marker improvements, total hemoglobin gains, VOC reduction trends, and no drug-related SAEs through 12 mg. Enrollment completed in the 20 mg cohort (n=12); data expected by year-end 2025. Financials: $200.6M cash and marketable securities as of Sept 30, 2025, with a cash runway into 2028. Q3 R&D $14.3M, G&A $7.6M, net loss $19.6M.

4 months ago

#FULC Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025

www.stocktitan.net/news/FULC/fulcrum-therap...

0 0 0 0

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 Fulcrum Therapeutics (NASDAQ:FULC) reported Q2 2025 financial results and clinical progress. The company announced promising results from the 12 mg dose cohort of the Phase 1b PIONEER trial for pociredir in sickle cell disease, showing an 8.6% mean increase in fetal hemoglobin and 67% F-cells, with no serious adverse events.Financial highlights include $214.1 million in cash reserves as of June 30, 2025, extending runway into 2028. Q2 2025 resulted in a net loss of $17.3 million, compared to net income of $55.4 million in Q2 2024. R&D expenses decreased to $13.0 million from $17.3 million year-over-year, while G&A expenses reduced to $6.8 million from $10.2 million.

7 months ago

#FULC Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025

www.stocktitan.net/news/FULC/fulcrum-therap...

0 0 0 0

Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease Fulcrum Therapeutics (NASDAQ:FULC) announced positive results from the 12 mg dose cohort of Phase 1b PIONEER trial for pociredir in sickle cell disease (SCD). The trial demonstrated a significant 8.6% absolute mean increase in fetal hemoglobin (HbF) after 12 weeks of treatment, with 7 of 16 patients achieving HbF levels above 20%.Key findings include pan-cellular HbF induction with F-cells increasing from 34% to 67%, meaningful improvements in hemolysis markers, and a 0.9 g/dL increase in total hemoglobin. The drug showed encouraging trends in reducing vaso-occlusive crises (VOCs) and maintained a favorable safety profile with no treatment-related serious adverse events.The study involved 135 adults across multiple cohorts, including 103 healthy subjects and 32 SCD patients, with all treatment-related adverse events being Grade 1.

7 months ago

#FULC Fulcrum Therapeutics Announces Results from the 12 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

www.stocktitan.net/news/FULC/fulcrum-therap...

0 0 0 0

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025 Fulcrum Therapeutics (NASDAQ: FULC) reported Q1 2025 financial results and business updates. The company completed enrollment in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial for pociredir in sickle cell disease and initiated the 20 mg dose cohort. Clinical data is expected in early Q3 2025 for the 12 mg cohort and by end of 2025 for the 20 mg cohort. The trial shows >90% drug adherence with no discontinuations. Financial highlights include: $226.6 million in cash/equivalents (vs $241.0M in Q4 2024), reduced R&D expenses of $13.4 million (vs $19.8M in Q1 2024), lower G&A expenses of $7.0 million (vs $10.1M in Q1 2024), and net loss of $17.7 million (vs $26.9M in Q1 2024). The company expects its current cash position to fund operations into at least 2027.

10 months ago

#FULC Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

www.stocktitan.net/news/FULC/fulcrum-therap...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

10 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with improving money flow, Wed Apr 16th - #KROS #FULC #CMPS #BCTX #ALDF #IHS #FBMS #EQC #AMPX #MFIN #NVVE #OMEX #VINC #BOWN #TIRX - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024 Fulcrum Therapeutics (Nasdaq: FULC) reported its Q4 and full year 2024 financial results, highlighting progress in its lead program, pociredir for sickle cell disease (SCD). The company has enrolled 10 patients in the 12 mg dose cohort of the Phase 1b PIONEER trial and expects to share clinical data from this cohort in mid-2025 and from the 20 mg dose cohort by year-end.Financial highlights include $241.0 million in cash, cash equivalents, and marketable securities as of December 31, 2024, providing runway into at least 2027. Full-year 2024 collaboration revenue was $80.0 million, primarily from a Sanofi upfront payment. R&D expenses decreased to $63.4 million for 2024 (from $71.8 million in 2023), while G&A expenses fell to $36.4 million (from $41.7 million). Net loss for 2024 was $9.7 million, significantly reduced from $97.3 million in 2023.Fulcrum also plans to submit an IND for Diamond-Blackfan anemia in Q4 2025 and will present data from its discontinued losmapimod program at the 2025 MDA Conference in March.

1 year ago

#FULC Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024

www.stocktitan.net/news/FULC/fulcrum-therap...

0 0 0 0

1 year ago

#FULC Fulcrum Therapeutics to Participate in Upcoming December Conferences

www.stocktitan.net/news/FULC/fulcrum-therap...

0 0 0 0

1 year ago

BREAKING NEWS: ( NASDAQ: #FULC ) Fulcrum Therapeutics Inc. (NASDAQ: FULC) Leading the Way in Thursday Trading Based on Percentage Gain

#StockMarket #News

1 0 0 0

1 year ago

BREAKING NEWS: ( NASDAQ: #FULC ) Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation

#StockMarket #News

1 0 0 0

1 year ago

JUST IN: ( NASDAQ: #FULC ) Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

#StockMarket #News

1 0 0 0

1 year ago

NEWS: ( NASDAQ: #FULC ) Bronstein, Gewirtz & Grossman, LLC Is Investigating Fulcrum Therapeutics, Inc. (FULC) And Encourages Investors to Connect

#StockMarket #News

1 0 0 0

1 year ago

Breaking News: ( NASDAQ: #FULC ) Fulcrum Therapeutics, Inc. (FULC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

#StockMarket #News

1 0 0 0

1 year ago

Just In: ( NASDAQ: #FULC ) Outperform Recommendation Issued On FULC By Oppenheimer

#StockMarket #News

0 0 0 0